ClinicalTrials.gg
CompletedNCT02632175Updated Oct 16, 2025Results posted

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

A Phase 3 interventional study of Adalimumab in Ulcerative Colitis, sponsored by AbbVie. Completed at 16 sites in 6 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
13th of 18
59 · median 152
Started
2015
the only one that year
Phase 3
10 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
4 of 18
AbbVie

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 10 in phase 3, and was the 12th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Subject must have successfully enrolled and completed M11-290 study

Exclusion criteria

Exclusion Criteria:

- Subject considered by the investigator, for any reason, to be an unsuitable candidate

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Subjects receiving Adalimumab

    Subjects receiving Adalimumab up to 288 weeks

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    every other week or weekly subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 70 days following last dose of study drug (up to 298 weeks).

  2. Proportion of Participants Who Achieve Clinical Remission as Measured by Partial Mayo Score (PMS)

    The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.

    Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288

  3. Proportion of Participants Who Achieve Clinical Response as Measured by PMS (From Study M11-290 Baseline)

    The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response was defined as a decrease in PMS ≥ 2 points and ≥ 30% from Study M11-290 Baseline.

    Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288

  4. Proportion of Participants Who Achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission

    The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). Clinical remission was defined as a PUCAI score \< 10.

    Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288

  5. Proportion of Participants Who Achieve PUCAI Response (From Study M11-290 Baseline)

    The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). PUCAI response was defined as a decrease in PUCAI score ≥ 20 points from Study M11-290 Baseline.

    Time frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288

07

Results

Posted Oct 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started59
Completed28
Not completed31
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up1
Withdrew: Lack of efficacy18
Withdrew: Required alternative (or prohibited) therapy1
Withdrew: Subject noncompliance3
Withdrew: Other2

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 70 days following last dose of study drug (up to 298 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAdalimumab
Any TEAE55
TESAE15
PrimaryProportion of Participants Who Achieve Clinical Remission as Measured by Partial Mayo Score (PMS)

The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical remission was defined as a PMS ≤ 2 and no individual subscore \> 1.

Time frame:
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Reported as:
Count of participants · Participants
Proportion of Participants Who Achieve Clinical Remission as Measured by Partial Mayo Score (PMS)
ParticipantsAdalimumab
Week 450
Week 847
Week 1251
Week 2443
Week 3645
Week 4840
Week 6042
Week 7242
Week 8440
Week 9636
Week 10837
Week 12033
Week 14432
Week 16831
Week 19230
Week 21629
Week 24028
Week 26427
Week 28825
PrimaryProportion of Participants Who Achieve Clinical Response as Measured by PMS (From Study M11-290 Baseline)

The Partial Mayo Score (PMS) is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Physician's Global Assessment (PGA), scored from 0 (normal) to 3 (severe disease). The overall Partial Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response was defined as a decrease in PMS ≥ 2 points and ≥ 30% from Study M11-290 Baseline.

Time frame:
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Reported as:
Count of participants · Participants
Proportion of Participants Who Achieve Clinical Response as Measured by PMS (From Study M11-290 Baseline)
ParticipantsAdalimumab
Week 456
Week 855
Week 1256
Week 2451
Week 3650
Week 4847
Week 6046
Week 7244
Week 8443
Week 9642
Week 10840
Week 12039
Week 14435
Week 16835
Week 19232
Week 21630
Week 24029
Week 26428
Week 28826
PrimaryProportion of Participants Who Achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission

The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). Clinical remission was defined as a PUCAI score \< 10.

Time frame:
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Reported as:
Count of participants · Participants
Proportion of Participants Who Achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission
ParticipantsAdalimumab
Week 450
Week 846
Week 1250
Week 2442
Week 3644
Week 4839
Week 6038
Week 7242
Week 8440
Week 9637
Week 10837
Week 12034
Week 14433
Week 16830
Week 19228
Week 21628
Week 24027
Week 26426
Week 28824
PrimaryProportion of Participants Who Achieve PUCAI Response (From Study M11-290 Baseline)

The Pediatric Ulcerative Colitis Activity Index (PUCAI) measures UC disease activity in children and adolescents by evaluating the following 6 areas: abdominal pain, number of stools per day, stool consistency, amount of blood in stools, nocturnal stooling, and activity level. The PUCAI score ranges from 0 to 85 with higher scores representing more severe disease. Recommended cut-off scores to differentiate disease activity are 0-9 (inactive), 10-34 (mild), 35-64 (moderate), and \> 65 (severe). PUCAI response was defined as a decrease in PUCAI score ≥ 20 points from Study M11-290 Baseline.

Time frame:
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Reported as:
Count of participants · Participants
Proportion of Participants Who Achieve PUCAI Response (From Study M11-290 Baseline)
ParticipantsAdalimumab
Week 447
Week 847
Week 1249
Week 2442
Week 3643
Week 4838
Week 6039
Week 7240
Week 8437
Week 9637
Week 10836
Week 12034
Week 14432
Week 16830
Week 19227
Week 21625
Week 24026
Week 26423
Week 28821

Adverse events

Collected over All-cause mortality were reported from enrollment up to 298 weeks, median time on follow up (median time subjects were followed) was 1723.0 days for adalimumab. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 70 days after the last dose of study drug; mean duration on study drug was 1354.2 days for adalimumab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab0/59 (0%)16/59 (27.1%)54/59 (91.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAdalimumab
COLITIS ULCERATIVEGastrointestinal disorders5/59
ANAEMIABlood and lymphatic system disorders2/59
LARGE INTESTINE POLYPGastrointestinal disorders2/59
BLOOD LOSS ANAEMIABlood and lymphatic system disorders1/59
DYSPEPSIAGastrointestinal disorders1/59
RECTAL HAEMORRHAGEGastrointestinal disorders1/59
CHOLECYSTITISHepatobiliary disorders1/59
BRONCHITISInfections and infestations1/59
LATENT TUBERCULOSISInfections and infestations1/59
LYMPH NODE ABSCESSInfections and infestations1/59
Most frequent other events
Showing 10 of 31
Most frequent other events
EventAdalimumab
COLITIS ULCERATIVEGastrointestinal disorders20/59
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations16/59
NASOPHARYNGITISInfections and infestations13/59
COVID-19Infections and infestations10/59
MYCOBACTERIUM TUBERCULOSIS COMPLEX TEST POSITIVEInvestigations10/59
HEADACHENervous system disorders9/59
PHARYNGITISInfections and infestations8/59
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/59
ANAEMIABlood and lymphatic system disorders7/59
ARTHRALGIAMusculoskeletal and connective tissue disorders6/59

Baseline characteristics

Integrated Full Analysis Set (IFAS) included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Adalimumab
Mean14.7 ± 3.26
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female30
Male29
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adalimumab
Hispanic or Latino1
Not Hispanic or Latino4
Unknown or Not Reported54
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adalimumab
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American2
White52
More than one race0
Unknown or Not Reported0
Proportion of Participants with Partial Mayo Score (PMS) Remission at Baseline
Proportion of Participants with Partial Mayo Score (PMS) Remission at Baseline(Participants)Adalimumab
Count of participants46
Proportion of Participants with PMS Response at Study M11-290 Baseline
Proportion of Participants with PMS Response at Study M11-290 Baseline(Participants)Adalimumab
Count of participants54
Proportion of Participants Who Achieve PUCAI Remission at Baseline
Proportion of Participants Who Achieve PUCAI Remission at Baseline(Participants)Adalimumab
Count of participants42
Proportion of Participants Who Achieve PUCAI Response at Study M11-290 Baseline
Proportion of Participants Who Achieve PUCAI Response at Study M11-290 Baseline(Participants)Adalimumab
Count of participants46
08

Study locations

16 sites
  • Arnold Palmer Hospital /ID# 147295
    Orlando, Florida 32806, United States
  • MNGI Digestive Health, P. A. /ID# 147294
    Minneapolis, Minnesota 55413-2195, United States
  • Mayo Clinic - Rochester /ID# 147304
    Rochester, Minnesota 55905-0001, United States
  • MultiCare Institute Health System /ID# 169005
    Tacoma, Washington 98405, United States
  • Kurume University Hospital /ID# 145710
    Kurume-shi, Fukuoka 830-0011, Japan
  • Juntendo University Hospital /ID# 147315
    Bunkyo-ku, Tokyo 113-8431, Japan
  • National Center for Child Health and Development /ID# 147312
    Setagaya-ku, Tokyo 157-8535, Japan
  • Uniwersytecki Szpital Dzieciecy w Krakowie /ID# 147279
    Krakow, Lesser Poland Voivodeship 30-663, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego /ID# 147310
    Wroclaw, Lower Silesian Voivodeship 50-369, Poland
  • Centrum Zdrowia MDM /ID# 147280
    Warsaw, Masovian Voivodeship 00-189, Poland
  • Gabinet Lekarski Bartosz Korcz /ID# 147281
    Rzeszów, Podkarpackie Voivodeship 35-210, Poland
  • Instytut Centrum Zdrowia Matki Polki /ID# 169017
    Lodz, Łódź Voivodeship 93-338, Poland
  • Univerzitna nemocnica Martin /ID# 147283
    Martin, Žilina Region 036 01, Slovakia
  • Hospital Universitario Vall d'Hebron /ID# 147288
    Barcelona, 08035, Spain
  • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 147290
    London, Greater London E1 2ES, United Kingdom
  • Duplicate_The Royal Free London NHS Foundation Trust /ID# 147292
    London, Greater London NW3 2QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Apr 2025, 112 months.

Results were first posted in Oct 2025, 6 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 112 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2015
First posted
Dec 16, 2015
StartActual
Nov 26, 2015
Primary completionActual
Apr 8, 2025
CompletionActual
Apr 8, 2025
Results first posted
Oct 16, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02632175
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 16, 2015
Start date
Nov 26, 2015
Primary completion
Apr 8, 2025
Completion
Apr 8, 2025
Results posted
Oct 16, 2025
Last update
Oct 16, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion